Long-term assessment of quality of life in the Intergroup Exemestane Study: 5 years post-randomisation

British Journal of Cancer

Volumn 106, Issue 6, 2012, Pages 1063-1067

  Fallowfield, L J ^a   Kilburn, L S ^b   Langridge, C ^a   Snowdon, C F ^b   Bliss, J M ^b   Coombes, R C ^c  

^a UNIVERSITY OF SUSSEX   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

aromatase inhibitor; breast cancer; exemestane; oestrogen receptor; quality of life

Indexed keywords

ESTROGEN RECEPTOR; EXEMESTANE; TAMOXIFEN; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR;

ARTICLE; BREAST CANCER; CANCER OF UNKNOWN PRIMARY SITE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FUNCTIONAL ASSESSMENT OF CANCER THERAPY SCALE; GASTROINTESTINAL SYMPTOM; GYNECOLOGIC DISEASE; HUMAN; LIBIDO; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NEUROLOGIC DISEASE; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; TREATMENT OUTCOME; VAGINA DISCHARGE; VASOMOTOR DISORDER; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG EFFECT; FOLLOW UP; METABOLISM; METASTASIS; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANDROSTADIENES; ANTINEOPLASTIC AGENTS; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG SUBSTITUTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIBIDO; NEOPLASMS, UNKNOWN PRIMARY; POSTMENOPAUSE; QUALITY OF LIFE; QUESTIONNAIRES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ESTROGEN; TAMOXIFEN; TREATMENT OUTCOME; VAGINAL DISCHARGE;

EID: 84858288976     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.43     Document Type: Article

References (13)

1. Addis IB, Van Den Eeden SK, Wassel-Fyr CL, Vittinghoff E, Brown JS, Thom DH, Reproductive Risk Factors for Incontinence Study at Kaiser Study Group (2006) Sexual activity and function in middle-aged and older women. Obstet Gynecol 107(4): 755-764
2. Atkins L, Fallowfield LJ (2007) Fallowfield0s Sexual Activity Questionnaire in women with without and at risk of cancer. Menopause Int 13(3): 103-109
3. Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE, Jassem J, Delozier T, Andersen J, Paridaens R, van de Velde CJ, Lønning PE, Morden J, Reise J, Cisar L, Menschik T, Coombes RC (2011) Disease related outcomes with long term follow-up: an updated analysis of the Intergroup Exemestane Study (IES). J Clin Oncol; doi:10.1200/JCO.2010.34.4010
4. Brady MJ, Cella DF, Mo F, Bonomi AE, Tulsky DS, Lloyd SR, Deasy S, Cobleigh M, Shiomoto G (1997) Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 15: 974-986 (Pubitemid 27106280)
5. Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A, ATAC Trialists' Group (2006) Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat 100: 273-284 (Pubitemid 44707921)
6. Cella D, Fallowfield LJ (2008) Recognition and management of treatmentrelated side effects for breast cancer patients receiving endocrine therapy. Breast Cancer Res Treat 107: 167-180 (Pubitemid 350265697)
7. Conde DM, Pinto-Neto AM, Cabello C, Sá DS, Costa-Paiva L, Martinez EZ (2005) Menopause symptoms and quality of life in women aged 45 to 65 years with and without breast cancer. Menopause 12(4): 436-443 (Pubitemid 41098657)
8. Fallowfield LJ, Leaity SK, Howell A, Benson S, Cella D (1999) Assessment of quality of life in women undergoing hormonal therapy for breast cancer: Validation of an endocrine subscale for the FACT-B. Breast Cancer Res Treat 55: 189-199 (Pubitemid 29389581)
9. Fallowfield LJ, Bliss JM, Porter LS, Price MH, Snowdon CF, Jones SE, Coombes RC, Hall E (2006) Quality of Life in the Intergroup Exemestane Study: A randomized trial of Exemestane versus continued Tamoxifen after 2 to 3 years of Tamoxifen in postmenopausal women with primary breast cancer. J Clin Oncol 24: 910-917 (Pubitemid 46638844)
10. Fallowfield L (2007) Quality of Life Issues in relation to the aromatase inhibitors. J Steroid Biochem Mol Biol 106(1-5): 168-172 (Pubitemid 47362651)
11. Schilder CM, Seynaeve C, Linn SC, Boogerd W, Beex LV, Gundy CM, Nortier JW, van de Velde CJ, van Dam FS, Schagen SB (2011) Self-reported cognitive functioning in postmenopausal breast cancer patients before and during endocrine treatment: findings from the neuropsychological TEAM side-study. Psychooncol; doi: 10.1002/pon.1928
12. Webster K, Cella D, Yost K (2003) The Functional assessment of chronic illness therapy (FACIT) measurement system: properties, applications, and interpretation. Health Qual Life Outcomes 1: 79
13. Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, Liu S, Shepherd LE, Palmer M, Robert NJ, Martino S, Muss HB (2005) Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 23: 6931-6940